DaTSCAN Brain Scintigraphy and Psychotropic Treatments: Influence on Radiotracer Binding
DAPSYFIX
1 other identifier
observational
300
1 country
1
Brief Summary
DaTSCAN™ (123I-ioflupnae) tomoscintigraphy assesses the density of dopamine transporters (DATs) on the presynaptic membrane of dopaminergic neurons. This examination is used in clinical routine in patients presenting a parkinsonian syndrome in search of a pre-synaptic dopaminergic denervation pointing to a neurodegenerative origin of this syndrome To date, there is little literature data evaluating the influence of psychotropic treatments frequently used in clinical routine on DaTSCAN™ CT images. Some studies have shown that SSRI (selective serotonin reuptake inhibitor) and SNRI (serotonin and norepinephrine reuptake inhibitor) antidepressants can significantly alter striatal ioflupane uptake ratios (10-20%) with no obvious influence on the visual interpretation of the examination . The objective of this study was to evaluate the influence of the most commonly used psychotropic therapies, sometimes in combination, on DaTSCAN™ CT images with a large population of patients included in clinical routine.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 5, 2023
CompletedFirst Posted
Study publicly available on registry
January 13, 2023
CompletedStudy Start
First participant enrolled
April 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2023
CompletedJuly 6, 2023
July 1, 2023
2 months
January 5, 2023
July 5, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
The influence of psychotropic treatments on radiotracer uptake during DaTSCAN™ tomoscintigraphies.
Binding ratios (specific binding ratio) stratum/occipital cortex, caudate nucleus/occipital cortex, putamen/occipital cortex on the left and right and total number of strokes recorded as a function of the presence or absence of psychotropic treatment at the time of examination
1 year
Interventions
DaTSCAN™ (123I-ioflupnae) tomoscintigraphy assesses the density of dopamine transporters (DATs) on the pre-synaptic membrane of dopaminergic neurons
Eligibility Criteria
All patients routinely referred for SPECT examination assessing the pre-synaptic dopaminergic pathway
You may qualify if:
- Patients with Parkinson syndroma
- Patients with Datscan in Nancy hospital bewteen septemnre 2019 and december 2022
You may not qualify if:
- Patient with a known allergy to any of the components of DaTSCAN™.
- Patient deprived of liberty by a judicial or administrative decision
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHRU Nancy
Vandœuvre-lès-Nancy, 54511, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD
Study Record Dates
First Submitted
January 5, 2023
First Posted
January 13, 2023
Study Start
April 1, 2023
Primary Completion
June 1, 2023
Study Completion
July 1, 2023
Last Updated
July 6, 2023
Record last verified: 2023-07